Swedish Orphan Biovitrum Total Liabilities 2019-2024 | BIOVF

Swedish Orphan Biovitrum total liabilities for the quarter ending June 30, 2024 were $3.439B, a 23.65% decline year-over-year.

  • Swedish Orphan Biovitrum total liabilities for 2023 were $3.787B, a 47.14% increase from 2022.
  • Swedish Orphan Biovitrum total liabilities for 2022 were $2.574B, a 13.3% decline from 2021.
  • Swedish Orphan Biovitrum total liabilities for 2021 were $2.968B, a 3.01% decline from 2020.

Swedish Orphan Biovitrum Total Liabilities 2019-2024 | BIOVF

  • Swedish Orphan Biovitrum total liabilities for 2023 were $3.787B, a 47.14% increase from 2022.
  • Swedish Orphan Biovitrum total liabilities for 2022 were $2.574B, a 13.3% decline from 2021.
  • Swedish Orphan Biovitrum total liabilities for 2021 were $2.968B, a 3.01% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$140.4B
Bristol Myers Squibb (BMY)$114.2B
Gilead Sciences (GILD)$113.5B
Vertex Pharmaceuticals (VRTX)$102.1B
CSL (CSLLY)$83.7B
Regeneron Pharmaceuticals (REGN)$77.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$37.8B
Alnylam Pharmaceuticals (ALNY)$30.8B
BioNTech SE (BNTX)$26.5B
Biogen (BIIB)$21.5B
Illumina (ILMN)$21.3B
BeiGene (BGNE)$17B
Moderna (MRNA)$15.2B
Genmab (GMAB)$13.3B
Incyte (INCY)$12.9B
Insmed (INSM)$12.4B
BioMarin Pharmaceutical (BMRN)$12.4B
Sarepta Therapeutics (SRPT)$11.4B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$10.7B
Exact Sciences (EXAS)$10.4B
QIAGEN (QGEN)$10.1B
Exelixis (EXEL)$9.6B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$8.9B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$8.4B
Repligen (RGEN)$8.2B
Jazz Pharmaceuticals (JAZZ)$7.4B